FDA OKs Elacestrant for ESR1+ Advanced, Metastatic Breast Cancer

January 28, 2023

The phase 3 data showed a 2-month progression-free survival benefit with elacestrant versus fulvestrant or an aromatase inhibitor.
Medscape Medical News

Read it later

LEAVE A REPLY Cancel reply

Time Management Tips

Recommended Tweets

Stand Up To Cancer ·
@SU2C

Klaus shares how a stage 3 melanoma diagnosis changed his life, and how cancer research and a clinical trial helped save it. 💛 #StandUpToCancer https://t.co/XD10pM4DWl

View on Twitter

Stand Up To Cancer ·
@SU2C

Today we celebrate SU2C’s 13th anniversary. In 2008, we began our mission to #StandUpToCancer. Because of donors and supporters like you, each day we are getting closer to a world with more long-term cancer survivors. Thank you for Standing Up with us for the last 13 years. 💛 https://t.co/BPSFt09TEr

View on Twitter

Stand Up To Cancer ·
@SU2C

Cancer research has the power to bring us one step closer to a world with more long-term survivors. This #CancerResearchMonth, you can be part of the next lifesaving breakthrough. Give now at https://t.co/tNxh7nWw6c. #StandUpToCancer https://t.co/2YI0bmJU9b

View on Twitter

Stand Up To Cancer ·
@SU2C

After being diagnosed with stage 4 #melanoma, a clinical trial helped Mary Elizabeth Williams defy the odds and survive cancer. She shares her inspiring story. #StandUpToCancer #MelanomaAwarenessMonth https://t.co/edeQjTUT0r

View on Twitter

Weather

Must Read

M	T	W	T	F	S	S
						1
2	3	4	5	6	7	8
9	10	11	12	13	14	15
16	17	18	19	20	21	22
23	24	25	26	27	28	29
30	31

FDA OKs Elacestrant for ESR1+ Advanced, Metastatic Breast Cancer

LEAVE A REPLY Cancel reply

Time Management Tips

Weather

Must Read

Awareness to Wellness: The Path to A World Without Cervical Cancer

A New Model for Oncology Second Opinion

High Discordance in Recs From Tumor Board and Sequencing Vendors

NTRK gene fusions as novel targets of cancer therapy across multiple tumour types

Chemo Is 'Invisible Threat' to Cancer Clinic Staff

POPULAR POSTS

Awareness to Wellness: The Path to A World Without Cervical Cancer

A New Model for Oncology Second Opinion

High Discordance in Recs From Tumor Board and Sequencing Vendors

POPULAR CATEGORY